Skip to main content

Table 1 Study dataset summary and key baseline patient characteristics

From: Development of a new Rasch-based scoring algorithm for the National Eye Institute Visual Functioning Questionnaire to improve its interpretability

Indication Trial n (%) Age (years) mean (SD, range) BCVA letter score at baseline mean (SD, range), Snellen equivalents
DME RESTORE [5] 344 (13.8) 64 (9, 37–87) 73 (11, 20/32)
96–40 (20/12–20/160)
Macular edema due to branch RVO BRAVO [28] 392 (15.8) 66 (12, 26–91) 82 (11, 20/25)
99–29 (20/10–20/250)
Macular edema due to central RVO CRUISE [27] 385 (15.5) 68 (13, 20–91) 81 (11, 20/25)
100–29 (20/10–20/250)
Neovascular AMD ANCHOR [25] 418 (16.8) 77 (8, 53–96) 68 (18, 20/40)
100–2 (20/10–20/1000)
Neovascular AMD MARINA [26] 716 (28.8) 77 (7, 52–95) 68 (15, 20/40)
99–19 (20/10–20/400)
CNV secondary to PM RADIANCE [8] 232 (9.3) 56 (14, 18–87) 73 (13, 20/32)
95–30 (20/12–20/250)
Overall population   2487 (100) 64 (9, 18–96) 73 (15, 20/32)
100–2 (20/10–20/1000)
  1. AMD age-related macular degeneration, BCVA best-corrected visual acuity, BSE better-seeing eye, CNV choroidal neovascularization, DME diabetic macular edema, PM pathologic myopia, RVO retinal vein occlusion, SD standard deviation, VEGF vascular endothelial growth factor